Can LDN treat chronic skin conditions

 The opioid-blocker naltrexone might prove effective in treating several chronic inflammatoryskin diseases, according to the several reviews of reports, case series, and random trials.

With ranging evidence, oral low-dose naltrexone proved successful in managing Hailey-Hailey disease, lichen planopilaris, and pruritus associated with scleroderma. As reported by Natasha Atanaskova of the University of California Irvine, and her colleagues:

"Naltrexone, particularly in low doses, has the potential to treat an array of primary skin lesions through inflammatory and immune-cell regulation and skin regeneration" and "Potential future uses include the treatment of diabetic wounds, bullous diseases, scarring alopecia, alopecia areata, and psoriasis."

Clinical evidence:

The researchers analyzed 22 articles, which involved randomized clinical trials, case series, and reports. Of the articles evaluated, 14 included high-dose naltrexone, 7 were dedicated to low-dose naltrexone, and 1 was on a topical formulation of 1% Naltrexone.

Concerning lichen planopilaris, there existed only one case series, however, low-dose naltrexone cured pruritus, reduced inflammation of the scalp, and delayed progression of the disease in all four subjects treated. No side effects occurred.

For Hailey-Hailey disease, the analysis was conducted over case series and reports of 11 patients treated with LDN. In one set giving 3.0 to 4.5 mg doses orally, cured lesions completely in 2 months duration in each of the three patients. The disease flared up on the discontinuation of the drug, but on restarting the treatment they got resolved.

High-dose naltrexone helped various kinds of pruritus but resulted in increased adverse effects. In a prospective cohort study conducted in2016 on 18 patients suffering pruritus from different causes. They were treated with a dose of 50-mg. The benefit was observed in 13 patients on the pruritus visual analog scale in 50% improvement. Adverse effects involved insomnia, anorexia, exhaustion, and constipation.

As we can also see that the trials are not backed up with clear and strong conclusions, the researchers did not approve naltrexone for treating all of the chronic inflammatoryskin diseases. They added: "However, research on animal models provides evidence that the medication may have several benefits on various aspects of skin disease. Among them are wound healing, anti-inflammatory effects, immunomodulation, and symptom control."

Conclusion:

It was concluded by the researchers that "Reports of naltrexone use, the theories behind its efficacy, and thus far its low number of adverse effects are highly valued" and "Future reporting is needed to determine appropriate conditions, dosing regimens, and long-term risks."